Although COVID-19 patients primarily manifest with respiratory tract symptoms, a growing number of studies have shown that ACE2 levels are significantly lower in the respiratory tract, relative to other organs such as the kidney, heart or the digestive tract, suggesting that other attachment and/or entry factors expressed in the host cell may compensate low or absence of ACE2 expression. This evidence concerns the gene ACE2 and COVID-19.